Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02109744 · ClinicalTrials.gov registry record · Phase 1
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02109744 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 27 participants.
The verdict
NCT02109744, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
To evaluate the response to chemotherapy with the drug decitabine combined with rapamycin in the treatment of relapsed or refractory acute myeloid leukemia in patients of all ages, and in the treatment of newly diagnosed leukemia in those who are older than 65 when diagnosed.
Interventions
- DRUG Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-03 |
| Est. Completion | 2022-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02109744
The ClinicalTrials.gov registry entry for NCT02109744 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine is the first listed.
NCT02109744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02109744 about?
NCT02109744 is a clinical study titled "Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients". To evaluate the response to chemotherapy with the drug decitabine combined with rapamycin in the treatment of relapsed or refractory acute myeloid leukemia in patients of all ages, and in the treatment of newly diagnosed leukemia in those who are older than 65 when diagnosed.
What is the current status of trial NCT02109744?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2014-03. Estimated completion is 2022-01-01.
What interventions are being tested in trial NCT02109744?
The interventions under investigation include: Decitabine (DRUG).
Who is sponsoring clinical trial NCT02109744?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.